



Changing cancer care together



All.Can at one year: a progress report

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (lead sponsor), Amgen, MSD and Johnson & Johnson (co-sponsors).

Contents

Section
01

Foreword

Section
02

2017 at a glance

Section
03

Highlights of the year

Section
04

Our events

Section
05

All.Can in print and video

Section
06

Building national initiatives

Section
07

What next for All.Can?

All.Can was launched at the European Parliament on 6 December 2016. In one year, it has grown from an idea to a fully operational and expanding movement, attracting membership from key figures in the world of cancer, leading engaging events and embarking on numerous exciting research projects. This document celebrates all that we have achieved over the past 12 months, and looks ahead to 2018 where we hope to become a truly global movement, unite different stakeholders and create meaningful, systemic change to drive high-quality, sustainable cancer care for patients in years to come.



'We have to put patients' needs first, because that is what it's really all about. What are we doing as physicians? As care givers? We are taking care of patients.'

Dr Matti Aapro
Clinique Genolier, Switzerland



Foreword



Kathy Oliver

Founding Co-Director and Chair of the International Brain Tumour Alliance (IBTA); Member of All.Can

Tackling inefficiency, waste and duplication requires our urgent attention as we face unprecedented pressure on national healthcare budgets. We need to sensibly sustain our systems in cancer care over the coming years and make sure that funds are wisely spent on the things that matter most to patients.

All.Can is a multi-stakeholder group, and the patient voice is reflected – through the active participation of international patient advocacy organisations – in everything we do.

So that we can amass a body of evidence to support our work, and provide pragmatic solutions to some of the challenges we face in helping to ensure sustainable cancer care, All.Can is endeavouring to collect practical examples of where inefficiencies exist. Patients tell us they are frustrated by the fact that, on the one hand, they need particular treatments, care or support but can't have them because of financial constraints and strains on their healthcare system, while on the other hand, inefficient healthcare practices abound.

We're not simply asking for more government funding to be injected into healthcare systems; it's about how the funds

that we have can be used more efficiently and directed to the benefit of patients.

To help achieve sustainable healthcare, it's crucial for all sectors to collaborate. Cancer is such a challenging and difficult disease, and none of us can fight it on our own. The silo approach has no place in cancer care.


I would like to see us making a real difference to cancer patients by reviewing inefficient and duplicative practices in our healthcare systems, by measuring the difference that our work has made, and by being able to say after a period of time: 'Yes, we identified that as an inefficiency. We suggested a better way which has really addressed what patients value on their journeys, and therefore we have significantly improved cancer patient outcomes.'

If you are interested in joining All.Can, we would welcome your participation. The more people we have involved in this initiative and the more perspectives we can represent, the faster the All.Can message will be disseminated and the more we can achieve. Cancer patients deserve no less.

What is All.Can?

All.Can (www.all-can.org) is an international multi-stakeholder initiative which was set up to identify ways we can optimise the efficiency of cancer care by focusing on improving outcomes for patients.

We believe that what matters to patients must always be at the heart of cancer care, and that all stakeholders must work together to ensure we allocate resources to prioritise interventions, technologies and models of care that improve patient outcomes, above all other considerations. This is key to the sustainability of cancer care.



Our members

All.Can currently has 20 members representing patient organisations, policymakers, healthcare professionals, research and industry. The interest and enthusiasm shown for the initiative is testament to the power of our message: that we must all work together to improve the sustainability of cancer care.



All.Can is currently funded by four companies: Bristol-Myers Squibb (BMS), MSD, Amgen and Johnson & Johnson. We are in active conversations with a variety of private sector companies and non-pharmaceutical organisations to join All.Can as well, to represent the breadth of cancer care both in our membership and funding base.

One of the highlights of 2017 was having the European CanCer Organisation (ECCO) join as a member of All.Can.

'The collaboration between ECCO and All.Can brings together 15 patient groups and 23 member societies, with over 100,000 cancer care professionals in all. My hope is that we continue the work we are doing, but we do it together.'

Dr Peter Naredi
ECCO



'What is unique about All.Can is its diversity of membership. All.Can platforms the exchange of best practices, and has an extensive programme of research and policy engagement to achieve its aims.'

Lieve Wierinck
MEP





2017 at a glance

2016

Dec

- Launch at the European Parliament

2017

Jan

- All.Can symposium at ECCO Congress

Mar

- All.Can UK report launched
- All.Can Poland officially launched

Jun

- All.Can Germany officially launched
- All.Can poster at British Neuro-Oncology Society conference

Jul

- Policy report published in the [Journal of Cancer Policy](#)

Sep

- All.Can Sweden officially launched
- Poster presented at ESMO 2017

Oct

- Policy workshop at European Health Forum Gastein
- Joint project with ICHOM announced at ICHOM conference
- All.Can Patient Masterclass at IBTA World Summit of Brain Tumour Patient Advocates

2018

Jan

- Patient survey UK pilot launched
- MEPs Against Cancer seminar in partnership with All.Can, European Cancer Patient Coalition (ECPC) and ECCO

Highlights of the year

A dual launch: European Parliament and ECCO Congress 2017

All.Can was officially launched at the European Parliament in December 2016, under the patronage of Lieve Wierinck MEP. We also launched our inaugural [policy report](#) on this date, as well as at a symposium at the ECCO Congress 2017 in Amsterdam.

Collecting data to drive policy: our research

Following the publication of the All.Can policy report, members decided it was crucial to gain a better understanding of what efficiency really means in cancer care, particularly from the patient perspective. This research is the backbone of All.Can's mission in 2018 and beyond: to create a set of practical, compelling policy recommendations that will meaningfully impact and improve the patient's experience of cancer care.




'There's active work going on. It will be evidence-based, and the methods will be published. The idea here is to make sure we really have a credible base of information that people can rely on and that we can form a consensus around.'

Dr Vivek Muthu
Marivek Healthcare Consulting



The All.Can approach to research



The All.Can patient survey is a core pillar of our research. The survey will cover multiple cancer types, beginning with a UK pilot and widening to a roll-out across nine further countries during 2018. All.Can is working with Quality Health to run this survey.

Findings will help identify the greatest opportunities to improve efficiency in cancer care in a way which is most meaningful to patients, and to guide policymakers on where they need to focus efforts to make the biggest difference to patient care. The findings will be launched at the ECCO summit in September 2018 in Vienna, Austria.

All.Can is also partnering with ECCO to undertake a quantitative and qualitative survey of the ECCO multidisciplinary membership – to gain insights from healthcare professionals on the topic of inefficiency in cancer care. Findings will be presented at the ECCO summit in 2018.



All.Can is partnering with the International Consortium for Health Outcomes Measurement (ICHOM), to measure the outcomes and costs associated with lung and breast cancer care, with a view to identifying what contributes to variations in outcomes and overall efficiency. These data will be used to track and measure quality improvements within these cancer care communities. This research will involve approximately nine cancer centres per indication, based in three or four European countries. Findings will be launched at the ICHOM conference in early 2019.



'All.Can is one of those rare initiatives that is able to draw together multiple stakeholders in making a practical change. The ICHOM–All.Can Improving Value Study represents a truly exciting opportunity to improve the quality and efficiency of care in breast and lung cancer, and inspire other providers to start measuring the value they are creating for their patients.'

Rishi Hazarika
ICHOM



Finally, we are leading a research paper looking at the role of data in driving efficiency and better outcomes in cancer care.



Our events

'Try wearing a different hat': All.Can workshop at European Health Forum Gastein

At the 20th anniversary of the [European Health Forum Gastein](#), All.Can led a popular workshop exploring the role of different stakeholders in improving efficiency in cancer care. We invited attendees to 'try wearing a different hat', or adopt a perspective other than their own, to look at possibilities of reducing inefficiencies across cancer care. Each table of participants represented a different sector, and was assigned a unique hat, which the attendees wore proudly.

The discussion yielded fascinating insights, which you can read about in our [outcomes report](#). One of the most compelling findings of the workshop was that focusing more on the patient perspective was always the first consideration on everybody's mind when talking about how we could improve efficiency across cancer care.

The uniqueness of All.Can, and its ability to bring all sectors and stakeholders together, was widely talked about after the session. One attendee mentioned how important it was to have an 'honest broker' like All.Can to bring together stakeholders with different agendas, to work towards a common goal – ultimately leading to better patient care.

October
2017



Click boxes below for links to All.Can published article and video resources

Invited article:
Brain Tumour magazine



Peer-reviewed publication:
Journal of Cancer Policy




Feature article:
Eurohealth



Thought Leader article:
The Parliament Magazine



Spotlight series:
Spotlight on cancer nurses



All.Can in print...

Over 2000 copies of our policy report have been distributed since its launch. The report has been translated into German, and was accepted as a peer-reviewed publication in the Journal of Cancer Policy.

All.Can has also published other articles over the course of the year (click the links to the left):

- Invited article:
Brain Tumour magazine
- Peer-reviewed publication:
Journal of Cancer Policy
- Feature article:
Eurohealth
- Thought Leader article:
The Parliament Magazine
- Spotlight series:
Spotlight on cancer nurses

...and in video

All.Can has created an animation, detailing the problems with inefficiency in cancer care, the possible solutions and the key areas we are focusing on. Click on the image to the left to see the animation.

All.Can has also been interviewing our members about their thoughts and feelings on why they joined the initiative. We are multi-stakeholder, aiming to encompass all sectors across cancer care, and it's vital that we give a voice to all our members. We will be releasing highlights from these interviews throughout 2018. In the first interview, Dr Matti Aapro and Dr Peter Naredi talk about the ECCO/All.Can collaboration.



Building national initiatives

All.Can understands that, while problems of inefficiency may be universal, the solutions to those problems will be unique to each country. As a result, we are launching national initiatives across Europe, Australia, Canada and beyond, to tackle inefficiency at a national level. Each initiative is fully independent and made up of members, and targeting policymakers, relevant to that country. We are all, however, still working toward the same goal: tackling inefficiency by putting the patient first.



'We need to look at the similarities and differences throughout Europe. We see many similar themes but different solutions. One of the challenges in All.Can is identifying multiple solutions to the same issue.'

Lydia Makaroff
European Cancer Patient Coalition

All.Can UK launched its report, [Transforming the Cycle in Cancer Care](#), at the UK Parliament in March 2017. The report sets out recommendations for transforming cancer care by identifying and implementing existing best practice throughout the NHS. A range of health charities from across the cancer community has contributed to the development of the programme, and the initiative has been supported and developed in partnership with one of the leading national charities, The Patients Association.



All.Can Poland was launched on 21 March, during the first panel of the 6th Oncology Patient Forum, organised by the Polish Coalition of Cancer Patients (PKPO). The event gathered around 200 participants, including the leading cancer patient groups, experts and decision-makers. Boleslaw Piecha MEP was in attendance and strongly supported the initiative, actively participating in both the panel and press conference.

All.Can Sweden was launched on 19 September 2017 with the announcement of the Cancer Commission.



'I hope and believe that we will be able to make a difference by producing concrete suggestions that will influence the decision makers. Many people speak about the need for better and fully functioning information technology that streamlines care pathways and strengthens the link between diagnostics and research. But we will look at the whole chain, from aspects which may preclude cancer to the follow-up care of the large number of people who will have had cancer and survived.'

Lars Leijonborg
Chairman, Cancer Commission



All.Can Germany was established at a kick-off event in November 2016, where members of the steering group convened to define key needs in German cancer care. It is undertaking a series of roadshow events across the country, providing a platform for stakeholders and policymakers to discuss crucial challenges in the current cancer patient pathway. The events aim to identify best practice at each location, with plans to develop a national white paper with results.



'All.Can combines defining quality measurement with identifying inefficiencies. That's why I like to work with All.Can; this is a combination we don't find in other organisations.'

Dr Rainer Hess
GVG-Committee
on Health Goals, Germany



What next for All.Can?

In 2018 we will continue to forge new alliances and put our ideas into action. We will also be advancing our research projects with the hope of gathering the evidence and data we need to drive real change at a policy and system level, which will ultimately improve cancer care for patients.


In January, we are holding a round table at the European Parliament with the MEPs Against Cancer (MAC) group, in collaboration with the ECPC and ECCO. We also plan to conduct a number of events to profile our research findings, including an All.Can session at the ECCO summit in Vienna in September.

Join us at one of our events, help us spread the word about how to improve efficiency in cancer care, and play an important part in helping deliver sustainable cancer care for all.



**'We cannot assume a single
outcome is valuable for patients.
We need constant communication.'**

Dr Tit Albreht
Institute of Public Health, Slovenia



Join us. Work with us. Together #WeAllCan.

www.all-can.org

[@AllCanGroup](https://twitter.com/AllCanGroup)

secretariat@all-can.org

All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (lead sponsor), Amgen, MSD and Johnson & Johnson (co-sponsors).



Changing cancer care together